NASDAQ: BOLDBoundless Bio Inc Stock
$11.64-0.43 (-3.56%)
Updated Apr 26, 2024
BOLD Price
$11.64
Fair Value Price
$0.97
Market Cap
N/A
52 Week Low
$9.83
52 Week High
$15.24
P/E
-0.29x
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$49.43M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.07
Operating Cash Flow
-$47M
Beta
1.4
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BOLD Overview
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BOLD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BOLD ($11.64) is overvalued by 1,103.41% relative to our estimate of its Fair Value price of $0.97 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BOLD ($11.64) is not significantly undervalued (1,103.41%) relative to our estimate of its Fair Value price of $0.97 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BOLD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BOLD due diligence checks available for Premium users.
Be the first to know about important BOLD news, forecast changes, insider trades & much more!
BOLD News
Valuation
BOLD fair value
Fair Value of BOLD stock based on Discounted Cash Flow (DCF)
Price
$11.64
Fair Value
$0.97
Overvalued by
1,103.41%
BOLD ($11.64) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BOLD ($11.64) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BOLD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BOLD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.29x
Industry
14.88x
Market
41.14x
BOLD's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
BOLD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$129.9M
Liabilities
$9.4M
Debt to equity
-0.07
BOLD's short-term assets ($124.20M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BOLD's short-term assets ($124.20M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BOLD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BOLD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
BOLD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
Boundless Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.